Antihypertensivetreatment in Russia (PIFAGOR III study results)

The article presents an analysis of pharmacotherapy in hypertensive patients (n = 3030) in real practice in Russia based on pharmacoepidemiologic study PIFAGOR III. Results. 784 patients (26 %) get monotherapy, 1126 patients (37 %) - combination of 2 drugs, 1120 patients (37 %) - 3 and more drugs. Average number of antihypertensive drugs is 2,22 per 1 patient. Antihypertensive efficacy by monotherapy (achieved blood pressure (BP) < 140/90 мм Hg) was 71 %. Angiotensin-converting enzyme (ACE) inhibitors (57,3 %), β-blockers (18,2 %), calcium antagonists (7,9 %), thiazide diuretics (7,3 %), angiotensin II (ATII) receptors antagonists (4,5 %) were used as monotherapy, and their antihypertensive efficacy was 70, 73, 60, 86, and 88 % , respectively. In hypertensive, diabetic patients (n = 638) the target BP (< 130/80 mmHg) was achieved by 31 % vs 69 % in general population, average number of antihypertensive drugs was 2,5 per 1 patient, combination therapy was used in 83,7 % patients vs 74 % in general population. ACE-inhibitors and ATII-receptors antagonists were used more frequently in patients with target BP. Among hypertensive patients with myocardial infarction (n = 423) the target BP reached 66 %, average number of antihypertensive drugs was 2,6 per 1 patient, combination therapy rate was 83,2 %. β-blockers were prescribed more often in this subgroup compared to general population. 46 % hypertensive patients with chronic heart failure (n = 980) achieved the target BP, average number of antihypertensive drugs was 2,4 per 1 patient, combination therapy use was the highest (86,2 %), in particular 3 and more drugs were prescribed to 57 % subjects.

pharmacoepidemiology, arterial hypertension, antihypertensive monotherapy, diabetes mellitus, chronic heart failure

1. Белоусов Ю.Б., Шляхто Е.В., Леонова М.В., и др. Результаты национального фармакоэпидемиологического исследования больных артериальной гипертонией - ПИФАГОР II // Качественная клиническая практика. - 2004. - № 1. - С. 1-26.

2.

3. Neaton J.D., Grimm R.H., Prineas R.J. et al. Treatment of mild hypertension study. Final results // J. Am. Med. Assoc. - 1993. - Vol. 270, № 6. - P. 713-724.

4.

5. Elliott W., Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis // Lancet. - 2007. - Vol. 369, № 9557. - P. 201-207.

6.

7. Bloom B.S. Continuation of initial antihypertensive medication after 1 year of therapy // Clin. Ther. - 1998. - Vol. 20, № 4. - P. 671-681.

8.

9. Conlin P.R., Gerth W.C., Fox J. et al. Four-year persistence pattern among patients initiating therapy with the angiotensin II receptor antagonists losartan versus other antihypertensive drugs classes // Clin. Ther. - 2001. - Vol. 23, № 12. - P. 1999-2010.

10.

11. Csaika C., Buclin T., Brunner H.R., Biollaz J. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists // Clin. Pharmacokinet. - 1997. - Vol. 32, № 1. - P. 1-29.

12.

13. Nayler W.G. Amlodipine. - Spring-Verlag, 1993. - P. 30-226